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be considered when prescription drug benefits are de-
signed.
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PUBLIC REPORT SPURS HOSPITAL 
MORTALITY REDUCTION
Czerwinski AA, Horgan MM
Care Management Science Corporation, Philadelphia, PA, USA
OBJECTIVE: The State Hospital Association (SHA) in a
large Midwestern state annually publishes risk-adjusted
mortality rates on selected groups of patients, by hospi-
tal. For the third year in a row, the SHA reported a
higher than expected mortality rate for Non-Surgical
‘Heart’ cases at Memorial, and the Board of Directors
asked for an improvement plan. METHODS: We used
the CaduCIS risk assessment methodology to indepen-
dently validate the SHA’s findings, and conducted oppor-
tunity analyses to identify a specific sub-population which
seemed to be the major contributor to the mortality rate.
RESULTS: (1) Most of the “excess” mortality seemed to
occur in medically managed AMI patients. (2) While a
few physicians cared for high volumes of such patients, a
surprising number of physicians had very low volumes.
(3) Risk-adjusted outcomes for the low-volume physi-
cians were significantly worse than predicted. (4) A non-
cardiologist was the attending physician for fully 25% of
the medically managed patients. (5) A small percentage
(4%) of medically managed AMI cases were admitted to
the Neuro ICU rather than the Cardiac ICU—but the
mortality rate in that subgroup was 58%—11% of the
total deaths. (6) Thrombolytic therapy was administered
to only 1% of medically managed AMI patients. (7) Beta-
blockers were administered to only 58% of patients. Im-
provement strategies included retargeting educational
programs, providing ongoing feedback on mortality rates,
and modifying clinical protocols. CONCLUSIONS: (1)
For the three-month time period following the implemen-
tation of improvement strategies for medically managed
AMI patients, the mortality rate decreased from 19% to
8%. (2) No AMI patients were admitted to the Neuro
ICU. (3) The proportion of AMI admissions directly
managed by cardiologists increased to 84%. (4) The fre-
quency of beta-blocker administration improved to 82%.
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PROGRAM (SCAP): IMPACT OF CLINICAL AND 
FUNCTIONAL STATUS AND TYPE OF 
MEDICATION TREATMENT ON OUTPATIENT 
PSYCHIATRIC UTILIZATION
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OBJECTIVE: To examine the impact of demographics,
clinical/functional status, and type of medication on out-
patient utilization for persons enrolled in the US Schizo-
phrenia Care and Assessment Program (SCAP). METH-
ODS: Baseline data was used to predict 6-month
outpatient utilization (n  530). Psychotherapy (individ-
ual and group), clinic (medical services for specimen col-
lection), and total number of outpatient visits (psycho-
therapy, clinic, day treatment, rehabilitation) were examined.
Adherence at baseline and at six months reflected the 4-
week period prior to each assessment. Negative binomial
regression was used and predicted values obtained
through joint determination (SURE) of clinical/functional
status were used in the models. Standard errors were ad-
justed. RESULTS: Psychotherapy Visits: Persons using
second-generation medications exhibited more psycho-
therapy visits than their counterparts using first-genera-
tion agents and adherence at baseline only exhibited a
positive association. Clinic Visits: Non-whites exhibited
fewer visits and adherence at baseline only was associ-
ated with more visits. Total Outpatient Visits: 1) Persons
in better health exhibited more visits; 2) adherence at
baseline only was positively associated with more outpa-
tient visits; and 3) higher PANSSGP was positively associ-
ated with total visits while higher MADRS exhibited a
negative association. Season of birth and site of service
were significant in the models. CONCLUSIONS: Clinical/
functional status, medication regimen, and medication
non-adherence are significant determinants of psychiatric
service utilization. The presence of second-generation
medications, better health, and adherence to medications
is associated with greater involvement in psychotherapy,
which suggests the possibility that these factors may pro-
mote community functioning.
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Using input from consumers, clinical staff, and quality of
life experts, we developed a self-administered, health-
related quality of life instrument for individuals with
schizophrenia living in the community—the Schizophre-
nia Outcomes Assessment Project 51-item Health Status
Survey (SOAP-51). OBJECTIVE: To establish the con-
current and discriminatory validity of the SOAP-51
Health Status Survey. METHOD: We asked 1500 indi-
viduals with schizophrenia and their caregivers in 5 eth-
nically and geographically diverse states to complete the
SOAP-51; retention was 84.2%. For concurrent valida-
tion, consumers were asked to globally rate the impact of
their condition on each of SOAP-51’s 8 factors; Cron-
bach’s alpha was 0.711–0.881, test-retest reliability was
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0.781–0.994. Factor scores were compared across self-re-
ported degree of impact. For discriminate validity, the
staff placed each consumer into one of 4 quartiles to de-
scribe their perception of the consumer’s ability to func-
tion in each factor area. Consumer factor scores then
were compared to staff-reported functional levels. RE-
SULTS: For all factors, consumer factor scores progres-
sively lowered as consumers felt the condition had more
negative impact on their lives (P  0.001). For all factors
but medication effects, consumer factor scores improved
with improving staff-perceived assessment of consumer
functionality (P  0.001). Consumer scores from the
lowest to the highest assigned quartile had average scores
of 42.7%, 49.3%, 54.7%, and 60.0%, respectively. 92%
of consumers considered the survey useful, 92% of staff
considered the survey valuable for monitoring consumer
progress. CONCLUSION: We have established concur-
rent and discriminatory validity for the SOAP-51 which
can be used as an outcomes measure in patient monitor-
ing and management, and health policy decision making. 
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OBJECTIVES: One of the most disconcerting symptoms
associated with Parkinson’s disease (PD) and essential
tremor (ET) is disabling tremor. Treatment options for
this problem include low-risk pharmacologic therapy,
with generally poor effectiveness and unfavorable side ef-
fects, or higher risk surgical interventions such as thalam-
otomy. We describe the health-related quality of life
(HRQL) of patients with disabling tremor and assess
their preferences for treatment outcomes in the form of
utilities. METHODS: The MOS Short-Form 36 (SF-36)
was used to characterize the patients’ HRQL. Standard
gamble (SG) and visual analog scale (VAS) approaches
were used to determine patient preferences among 12 PD
and 9 ET health state descriptions. Data on patients’ ap-
praisal of their current health state were also correlated
with indicators of functional disability (Schwab & En-
gland) and HRQL (SF-36) using Spearman’s Rho (	). RE-
SULTS: Sixty-two patients, 31 tremor-dominant PD and
31 ET, participated in the study. Mean age of the sample
was 65 years; 65% (n  40) were male. PD and ET pa-
tients assigned the lowest mean SG health utilities to the
health state description for a thalamotomy with partial
or no improvement and permanent cognitive impairment
(mean  standard deviation: PD: 0.56  0.25 and ET:
0.49  0.27). The highest mean utilities were assigned to
thalamotomy with full improvement and no permanent
impairment (PD: 0.95  0.02 and ET: 0.90  0.18). Cur-
rent health state SG utilities were highly correlated with
indicators of disability and HRQL (	  0.35 to 0.64).
CONCLUSIONS: Results suggest these patients are rela-
tively risk averse. Subjects preferred disability associated
with tremor over disability associated with cognitive or
speech impairment that can occur with thalamotomy.
The greatest patient-to-patient variability was found in
the least desirable health states.
Q3
HEALTH-RELATED QUALITY OF LIFE (HRQOL) 
IN AFRICAN AMERICAN MEN WITH PROSTATE 
CANCER: DATA FROM CaPSURE
Lubeck DP1, Grossfeld G1, Ray P2, Flanders SC3, Carroll PR1
1Department of Urology, University of California, San 
Francisco, CA, USA; 2Cook County Hospital, Chicago, IL, USA; 
3TAP Holdings, Deerfield, IL, USA
OBJECTIVES: To compare clinical characteristics, treat-
ment choices, sociodemographic features, baseline and
follow-up HRQOL of African American (AA) and Cau-
casian men with prostate cancer. METHODS: 1178 newly
diagnosed patients (82% Caucasian, 12% AA) from the
CaPSURE database (a national database of patients with
prostate cancer) were studied. Baseline cancer stage,
grade, PSA, comorbidity, treatment selection and base-
line and post-treatment HRQOL were assessed using the
SF-36 and the UCLA Prostate Cancer Index. The impact
of ethnicity on these outcomes was determined. RE-
SULTS: Significant differences (P  0.001) were noted
between ethnic groups. AA men were younger, less edu-
cated and had lower income than Caucasians. AA men
were more likely to have high-stage (i.e. N or M)
(10% vs. 1%) disease and higher pretreatment PSA (12.7
ng/ml vs. 7.5 ng/ml). AA men were more commonly
treated with androgen deprivation (37% vs. 26%). Clini-
cally and statistically significant (
  7, P  0.001) dif-
ferences in baseline HRQOL were noted in AA men who
had poorer: General Health, Physical Function, Bodily
Pain, Role Emotional Function, Sexual Bother, Self Es-
teem, and Health Distress. While both groups improve in
HRQOL 18 months after treatment, AA had worse out-
come in several domains: Bodily Pain, Self Esteem, Health
Distress, Physical Function, General Health, Role Emo-
tional, Urine Function and Bother, Bowel Function and
Bother. Differences were statistically and clinically signif-
icant. CONCLUSIONS: Significant differences exist in
baseline clinical presentation, sociodemographics, and
general HRQOL between AA and Caucasian men with
prostate cancer. These differences remain after treatment.
Interventions, which might reduce these differences, need
to be developed.
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